Deferoxamine mesylate, Iron chelator (ab120727)
Key features and details
- Iron chelator
- CAS Number: 138-14-7
- Soluble in water to 100 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Deferoxamine mesylate, Iron chelator -
製品の詳細
Iron chelator -
別名
- desferal
- desferrioxamine B
-
生理活性の詳細
Iron chelator. Blood-brain barrier permeable. Displays a number of biological actions such as immunomodulation, inhibition of inflammation and atherosclerosis, and reduction of neuronal death.
-
CAS 番号
138-14-7 -
構造式
製品の特性
-
体系名
N4-[5-[[4-5-(Acetylhydroxyamino)pentyl]-1,4-dioxobutyl]hydroxyaminopentyl-N1-(5-aminopentyl)-N1-hydroxybutanediamide methanesulfonate -
分子量
656.79 -
分子式
C25H48N6O8.CH3SO3H -
PubChem 登録番号
62881 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in water to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O -
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120727の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
画像
-
Chemical Structure - Deferoxamine mesylate, Iron chelator (ab120727)2D chemical structure image of ab120727, Deferoxamine mesylate, Iron chelator
-
Functional Studies - Deferoxamine mesylate, Iron chelator (ab120727)Titration of HeLa-DFO extract within the working range of the assay. Background subtracted data from duplicate measurements are plotted. To induce HIF1 alpha protein levels, HeLa cells were treated with 500 µM DFO (ab120727) for 24 hours. -
Deferoxamine mesylate, Iron chelator (ab120727)Dose-dependent induction of HIF1 alpha in HeLa cells by DFO (ab120727). HeLa cells were cultured in 96-well tissue culture plates and were either untreated or exposed to varying dose of DFO for 24 hours. Raw data with standard deviation is plotted from triplicate measurements.
Dose-dependent induction of HIF1 alpha in HeLa cells by DFO (ab120727). HeLa cells were cultured in 96-well tissue culture plates and were either untreated or exposed to varying dose of DFO for 24 hours. Raw data with standard deviation is plotted from triplicate measurements. -
Deferoxamine mesylate, Iron chelator (ab120727)Comparison of HIF1 alpha expression in HeLa cell extracts (with and without DFO treatment) by SimpleStep ELISA (barchart) and western blot (top). Background subtracted OD450 nm data from three loading concentrations are shown. The HIF1 alpha detector antibody was used to blot the same lysates as analyzed by SimpleStep ELISA (40 µg loaded/lane). The GAPDH blot is included to show the relative loads of each lysate. In the HeLa cell line, DFO treatment is required to detect HIF1 alpha protein by both SimpleStep ELISA and western blot.
Comparison of HIF1 alpha expression in HeLa cell extracts (with and without DFO treatment) by SimpleStep ELISA (barchart) and western blot (top). Background subtracted OD450 nm data from three loading concentrations are shown. The HIF1 alpha detector antibody was used to blot the same lysates as analyzed by SimpleStep ELISA (40 µg loaded/lane). The GAPDH blot is included to show the relative loads of each lysate. In the HeLa cell line, DFO treatment is required to detect HIF1 alpha protein by both SimpleStep ELISA and western blot.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (11)
ab120727 は 11 報の論文で使用されています。
- Yan B et al. Pharmacological inhibition of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) induces ferroptosis in vascular smooth muscle cells. Cell Death Discov 9:456 (2023). PubMed: 38097554
- Henning Y et al. Hypoxia aggravates ferroptosis in RPE cells by promoting the Fenton reaction. Cell Death Dis 13:662 (2022). PubMed: 35906211
- You JH et al. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells. J Exp Clin Cancer Res 40:350 (2021). PubMed: 34749765
- Tadokoro T et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight 5:N/A (2020). PubMed: 32376803
- Rakshit J et al. Iron chelator Deferoxamine protects human neuroblastoma cell line SH-SY5Y from 6-Hydroxydopamine-induced apoptosis and autophagy dysfunction. J Trace Elem Med Biol 57:126406 (2020). PubMed: 31570251